Atlas Trials

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

Clinical trial NCT02639338 · COMPLETED

Trial details

NCT number
NCT02639338
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis C Virus Infection
Start date
2015-12-23
Primary completion
2016-10-12
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.